Introduction
The main goals of initial induction chemotherapy for acute myeloid leukemia (AML) are rapid disease control through achievement of complete remission (CR), long-term survival, and low relapse rates with minimal induction toxicity. The 7+3 regimen combining an anthracycline (daunorubicin [DNR] ) with cytarabine has formed the backbone of AML induction for decades. Modification of DNR 45 mg/m 2 to idarubicin (IDA) 12 mg/m 2 has resulted in an improved curative effect and fewer adverse events. 1, 2 In 2010, the National Comprehensive Cancer Network (NCCN) recommended IDA 12 mg/m 2 as the first-line induction dosage. However, it remains unclear if the submit your manuscript | www.dovepress.com
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Zhou et al increased dose of IDA is positively correlated with superior efficacy. Pautas et al reported no significant differences in relapse incidence, event-free survival, or overall survival (OS) among IDA3 (12 mg/m 2 ×3) and IDA4 (12 mg/m 2 ×4) arms of the ALFA-9801 study. 3 The Chinese clinical practice guidelines for AML (nonacute promyelocytic leukemia; 2011 edition) recommended IDA 8-12 mg/m 2 combined with cytarabine as the initial 3 days idarubicin and 7 days cytarabine regimen for adult AML patients. However, there are no data indicating whether IDA 12 mg/m 2 is superior to IDA 8 mg/m 2 . This study aimed to explore a suitable dose of IDA combined with cytarabine as the first induction regimen for adults with AML by comparing the treatment effects and adverse reactions of IDA 12 mg/m 2 and IDA 8 mg/m 2 .
Patients and methods
A total of 100 cases of adult de novo acute AML (excluding acute promyelocytic leukemia) were enrolled in the current study at the Department of Hematology of Anhui Provincial Hospital from January 1, 2009, to June 30, 2014. The patients were randomized into two arms: the IDA 12 mg/m 2 arm and the IDA 8 mg/m 2 arm. The diagnosis of AML was based on WHO criteria, and AML was classified according to the French-American-British classification. The cytogenetic prognostic grouping criteria were classified according to the NCCN clinical practice guidelines for AML (nonacute promyelocytic leukemia; 2008 edition). All the patients were diagnosed as de novo AML. The patients were eligible for inclusion in the study if they were 14-80 years of age, had a pathologically confirmed diagnosis, and had at least 20% myoblasts in the bone marrow. Bone marrow smears from all patients were examined by May-Giemsa staining. Cytogenetic abnormalities were detected by conventional G banding. 4 We stratified the patients into risk groups based on cytogenetic and molecular analyses of bone marrow samples collected at diagnosis prior to any treatment according to the NCCN clinical practice guidelines for AML. 5 Induction therapy included a standard IA regimen (IDA 12 mg/m 2 once daily intravenously [iv] from days 1 to 3 combined with cytarabine 100 mg/m 2 once daily continuous iv from days 1 to 7).
1 A low-dose IA regimen was also used (IDA 8 mg/m 2 once daily iv from days 1 to 3 combined with cytarabine 100 mg/m 2 once daily continuous iv from days 1 to 7). The patients received another IA regimen if they did not achieve CR. Subsequently, four to six courses of intermediatedose cytarabine (1-2 g/m 2 twice daily iv over 3 hours from days 1 to 3) were administered as consolidation chemotherapy. Patients in adverse cytogenetic group who were in CR after consolidation chemotherapy and who had an HLA-matched donor could undergo allogeneic stem cell transplantation. Follow-up was performed until December 31, 2014.
The study protocol samples were approved by the ethics committee of Anhui Provincial Hospital and were conducted in accordance with the Declaration of Helsinki. All the patients gave written informed consent.
Definitions and study end points
The primary end points were OS, disease-free survival (DFS), and morphology leukemia relapse (hematological and/or extramedullary). OS was defined as the duration from diagnosis to death from any cause, and DFS was defined as the time from achieving CR until relapse or death. For analyses of DFS, failures were considered clinical or hematological relapse or deaths from any cause; patients alive and in CR were censored at the last follow-up. For analyses of OS, failures were considered death from any cause; alive patients were censored at the date of last contact. A secondary end point was the comparison of CR rates in the two study arms.
statistical analyses
The data in our study were statistically analyzed using the Statistical Package for Social Science (SPSS version 19.0; IBM Corporation, Armonk, NY, USA) and R 2.10.1 (Lucent Technologies, Muray Hill, NJ, USA). Statistical significance was considered at P-values ,0.05. All reported P-values are two sided. Differences in continuous variables were analyzed by two independent samples t-tests and chi-square tests; Fisher's exact test was performed to compare incidences. The Kaplan-Meier method and life table were performed to estimate the survival probabilities, and a log-rank test was used for univariate comparison. 6 Cumulative incidence curves for nonrelapse mortality and relapse with or without death were constructed reflecting time to relapse and time to nonrelapse mortality as competing risks. OS and DFS were compared using a log-rank test and a Cox proportional hazards model.
Results
Patient characteristics
The current study comprised 100 de novo AML patients, including 57 males and 43 females. The demographic and disease characteristics of the patients are listed in 
adverse events
All patients experienced severe bone marrow suppression and hematological toxicities. No patients suffered from early death in the IDA 12 mg/m 2 arm. Two patients died early (within 30 days) in the IDA 8 mg/m 2 arm. This difference was not statistically significant (P=0.300). The infection rates were 95.6% and 92.3% in the two arms, a difference that was not significant (P=0.439). Meanwhile, there was no significant difference in serious infections such as pulmonary, bloodstream, and fungal infections. The median durations for stable recovery of neutrophils to 0.5×10 9 /L and platelets to 20×10 9 /L were 13 (range: 0-33) days and 
Os and DFs
After a median follow-up of 13 (1-70) months from diagnosis until December 31, 2014, the 1-year and 2-year expected OS rates were 83.0% and 83.0%, respectively, in the IDA 12 mg/m 2 arm. The rates were 79.0% and 40.0% in the IDA 8 mg/m 2 arm. The median OS was 54.0 months vs 26.7 months in the two arms (P=0.021, by log-rank test; Table 3 ). The 1-year and 2-year expected DFS were 75.0% and 67.0% in the IDA 12 mg/m 2 arm and 51.0% and 36.0% in the IDA 8 mg/m 2 arm, respectively. The median DFS was 54.0 months vs 18.3 months (P=0.031, by log-rank test) in the two arms ( Table 3) .
Effect of cytogenetic profile
The CR rates for the favorable, intermediate-risk, and adverse groups were 92.3%, 77.4%, and 60%, respectively (P=0.072 for overall comparisons). The expected OS rate was higher in the IDA 12 mg/m 2 arm than in the cytogenetic intermediate-risk group. The median OS was 54.0 months vs 29.5 months (P=0.009, by log-rank test; Table 3 ). The median DFS was 54 months vs 15.3 months in the two arms in the cytogenetic intermediate-risk group (P=0.018, by logrank test; Table 3 ). The worst outcome was observed in the subgroup with an adverse cytogenetic profile; the median survival was 20.2 months and 18.9 months for the two treatment arms, a difference that was not significant (P=0.914, by log-rank test). However, the interaction between the treatment assignment and the cytogenetic profile was not significant.
effect of age
For the people younger than 55 years, the OS of patients in the 12 mg/m 2 arm was significantly longer than in the 8 mg/m 2 arm (P=0.017, by log-rank test). For the people older than 55 years, there is a trend that the OS of patients in the 12 mg/m 2 arm was longer than in the 8 mg/m 2 arm, but there is no statistically significant difference of OS between these two dose arms (P=0.364, by log-rank test).
Discussion
It has been postulated that one of the most effective ways to achieve higher CR rates and OS among patients with AML is to increase the induction dose of anthracyclines. 7 Trials of various chemotherapeutic agents have reported an improved CR rate among patients receiving high-dose DNR. 8, 9 Several trials have compared IDA and DNR, but only a few studies have focused on the dose of IDA. In this trial, we evaluated the effect of IDA dose intensity on remission induction in patients with de novo AML.
In our study, the CR rate was higher in the IDA high-dose arm than in the low-dose arm. However, this difference was not significant, and a larger patient sample may be needed. The CR rates attained in this trial were higher than those observed in previous studies such as the ECOG study, which used DNR and contained more patients older than 50 years. 10 However, the CR rates observed in the present study are similar to those reported in the ALFA-9801, AML-92, and JALSG AML201 studies. 
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Zhou et al were observed among the three arms. 3 In the present study, the CR rate was clearly higher for the two courses of highdose IDA than for the low dose, indicating a stronger effect of high-dose IDA in refractory AML patients. In the adverse group, the CR2 rate was higher in the IDA 12 mg/m 2 arm. The failure to observe a significant difference may be due to an insufficient number of cases; in our study, we had only 15 cases in the cytogenetic adverse group. IDA decreased the proportion of patients with resistant disease after induction, particularly in the immediate-risk group. Carella et al reported similar results in 1993; IDA in combination with intermediate-dose cytarabine and VP-16 had a good effect in refractory or rapidly relapsed AML patients. 13 The higher dose of 12 mg/m 2 of IDA did not significantly increase the frequency of adverse events or the hospital cost of induction therapy. Taken together, however, the present study and previous studies do not provide definitive proof that an increased dose of IDA improves CR rates. Pashko et al evaluated the cost of 120 untreated AML patients randomly assigned to receive 12 mg/m 2 of IDA or 50 mg/m 2 of DNR daily for 3 days with 200 mg/m 2 of cytosine arabinoside daily for 5 days. The costs per CR and per year of survival were lower for the IDA patients than for the DNR patients. We observed similar results in the present study. The cost of the first remission induction therapy did not differ between the two dosage arms. The hospital charges per year of survival were not evaluated but should be lower in the IDA 12 mg/m 2 arm due to the longer survival of patients in this arm. Pashko et al suggested that the lower remission rate in DNR-treated patients and their consequent need for additional care would increase the cost differences between the two treatments. IDA is more cost-effective than DNR for the treatment of adult AML. 14 In our study, lower relapse incidence and no-relapse mortality were observed after timed sequential induction in the IDA high-dose arm. The failure to observe a significant difference may be due to an insufficient number of cases or the short flow up.
In the present study, we observed significant improvements in OS among patients who received high-dose 12 2 of IDA (by either cytarabine intensification or stem cell transplantation) and anticipate excellent outcomes. A high dose of IDA provided no benefit in some of the patients in adverse cytogenetic profile in our study. The result is similar to the outcomes of the ECOG trial. 16 Other treatments were required for the adverse group, because the elevated dose did not change long-term survival. For the elderly patients, there is a trend that the OS of patients in 12 mg/m 2 arm was longer than that in 8 mg/m 2 arm in our study, but there is no statistically significant difference probably because of the rare case. Some other studies thought that a reduced dose might be superior. Flasshove et al observed improved OS at 5 years for patients up to 50 years of age vs patients older than 50 years of age and improved DFS and OS with a normal (vs unfavorable) karyotype.
17
A Japanese study examined the effect of decreased-dose IDA (12 mg/m 2 X2) for elderly AML patients and observed an improved 2-year OS rate and lower 2-year relapse-free survival among elderly patients of 65-74 years of age compared with younger patients, which suggests that elderly patients would benefit from a reduced dose of IDA. 18 The results of these two studies are not consistent with our results. Considering that we only have 10 and 11 patients in these two arms, further study needs to be done with more patients.
Our study suggests that IDA 12 mg/m 2 combined with cytarabine is a suitable regimen for initial remission induction treatment in adults with de novo AML (nonacute promyelocytic leukemia). The IDA 12 mg/m 2 dose is safe without significant adverse reactions. The regimen was well tolerated by the patients and did not result in increased hospital costs. 
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